A bispecific antibody targeting CD20 / CD3 and its preparation method and application
By designing CD20×CD3 bispecific antibodies with specific structures, the problems of serious adverse reactions in clinical applications of existing antibodies are solved, efficient tumor killing and low toxic side effects are achieved, and the treatment effect is significantly improved.
Patent Information
- Application Number
- CN202411045797.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-01
AI Technical Summary
The existing CD20×CD3 bispecific antibodies are prone to cause serious adverse reactions in clinical applications, such as cytokine storms and neurotoxicity, resulting in limited treatment windows.
A bispecific antibody with a specific structure was designed, including the scFv structure of anti-CD20 antigen and the Fab structure of anti-CD3 antigen. By optimizing the light chain variable region FR4 sequence and Fc region of the antibody, a "three-chain structure" was formed. To increase the expression of antibodies and tumor killing activity, while reducing the level of cytokine release.
It has achieved strong tumor killing activity and low toxic side effects, significantly improving the therapeutic window for the treatment of B-cell lymphoma and autoimmune diseases, and can effectively clear CD20-positive target cells and reduce the level of cytokine release.
Smart Images

Figure CN118562015B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology and relates to a bispecific antibody and a preparation method and application thereof. Background Art
[0002] B cells are an important part of the immune system. They are derived from multifunctional stem cells in the bone marrow and differentiated and developed from hematopoietic stem cells in the bone marrow. Studies have shown that when B cells undergo malignant mutations at a certain stage of development, they can proliferate uncontrollably and form tumors. B cell lymphoma is a malignant tumor of the lymphatic system, which has many types. In addition, B cells are at the core of the pathogenesis of a variety of autoimmune diseases by presenting antigens, secreting cytokines, and producing autoantibodies. In recent years, the incidence of autoimmune diseases has shown a clear upward trend, becoming the third largest chronic disease after cancer and cardiovascular disease. Targeted B cell therapy can inhibit the activation and proliferation of B cells and reduce the production of autoantibodies. Therefore, B cell clearance has become the main strategy for the treatment of autoimmune diseases in recent years.
[0003] T cells are a type of lymphocytes derived from the bone marrow. After the lymphoid progenitor cells in the bone marrow enter the thymus, they continue to differentiate and develop to form mature T cells with high diversity. T cell-mediated cellular immunity plays an important role in the body's resistance to disease infection and tumor clearance. The first stage of cellular immunity requires T cell antigen receptors (TCR) to recognize antigens. TCR is expressed on the surface of all mature T cells and is a specific receptor for T cells to recognize and bind to foreign antigens. The TCR of most T cells (about 95%) is composed of α and β chains, and a small part is composed of γ and δ chains. During the development of T cells, the encoded α and β genes determine the high polymorphism of TCR. Different T cell clones have different TCRs and can recognize different antigen epitopes (determinants). Since the intracellular domains that make up each chain of TCR do not have the function of signal transduction, they need to rely on their adjacent CD3 molecules to transmit activation information to the cell. Therefore, CD3 is considered to be an essential molecule in the process of T cell activation.
[0004] As an ideal target for B-cell lymphoma and B-cell-related autoimmune diseases, CD20 has always been a hot spot for the development of targeted drugs for B-cell-related diseases. Currently, monoclonal antibodies targeting CD20 have developed to the third generation and play an important role in the treatment of B-cell lymphoma and B-cell-related autoimmune diseases. Although anti-CD20 monoclonal antibodies have achieved certain therapeutic effects in the treatment of B-cell lymphoma and B-cell-related autoimmune diseases, many patients cannot get relief due to the limitations of monoclonal antibodies, and a new generation of biological agents targeting CD20 needs to be developed.
[0005] Bispecific antibodies have the ability to recognize and bind to two different antigens or antigenic epitopes, which gives them biological activity that monoclonal antibodies or combination therapies do not have, thus demonstrating great therapeutic potential. T cell-engaging bispecific antibodies can simultaneously bind to CD3 on T cells and specific antigens on tumor cells, bridging T cells and tumor cells. Through the first and second signals, they activate and guide T cells to secrete granzymes, perforins, etc. to kill tumor cells. For example, bispecific antibodies that bind to CD20 and CD3 at the same time can recruit T cells to tumor cells expressing CD20 protein, resulting in CD20-positive tumor cells being killed and cleared by T cells.
[0006] At present, CD20×CD3 bispecific antibodies are prone to cause serious adverse reactions in clinical applications, such as cytokine storm (CRS) and neurotoxicity. Therefore, it is necessary to construct a CD20×CD3 bispecific antibody molecule with strong cell killing activity and the ability to reduce cytokine release levels to increase the clinical treatment window. Summary of the invention
[0007] In view of the deficiencies of the prior art and actual needs, the present invention provides a bispecific antibody and a preparation method and application thereof, and develops a bispecific antibody targeting CD20 and CD3 with strong lethality and low toxic side effects. The antibody can mediate T cells to kill CD20-positive target cells in a specific manner and at the same time cause a lower level of cytokine release, thereby providing a larger treatment window in the treatment of B cell lymphoma and B cell-related autoimmune diseases.
[0008] To achieve the above object, the present invention adopts the following technical solutions:
[0009] In a first aspect, the present invention provides a bispecific antibody, the bispecific antibody comprising a first antigen binding domain, a second antigen binding domain and an Fc fragment, the first antigen binding domain being a scFv structure, the C-terminus of the framework region FR4 of the light chain variable region in the scFv structure being deleted by two or three amino acids, and the amino acid sequence of the framework region FR4 of the light chain variable region comprising the sequence shown in SEQ ID No.10, SEQ ID No.11 or SEQ ID No.12; the second antigen binding domain being a Fab structure; the sequences of the heavy chain CDR1, CDR2 and CDR3 of the scFv structure comprising the sequences shown in SEQ ID No.13, SEQ ID No.14 and SEQ ID No.15, respectively, and the sequences of the light chain CDR1, CDR2 and CDR3 comprising the sequences shown in SEQ ID No.16, SEQ ID No.17 and SEQ ID No.18, respectively; the sequences of the heavy chain CDR1, CDR2 and CDR3 of the Fab structure comprising the sequences shown in SEQ ID No.19, SEQ ID No.20 and SEQ ID No.21, respectively. The sequences of the light chain CDR1, CDR2 and CDR3 include the sequences shown in SEQ ID No.22, SEQ ID No.23 and SEQ ID No.24, respectively.
[0010] In the present invention, a bispecific antibody with a specific structure is designed, which has a "three-chain structure" consisting of a first antigen binding domain of an scFv structure of an anti-CD20 antigen, a second antigen binding domain of an Fab structure of an anti-CD3 antigen, and an Fc region, and has strong tumor killing activity. In addition, the FR4 sequence of the light chain of the scFv structure of the anti-CD20 antigen is optimized and modified, and two or three amino acids at the C-terminus are deleted, which can further increase the antibody expression amount and the ability to bind to CD20-positive cells. In particular, the deletion of specific amino acids can further increase the killing activity against tumor cells, reduce toxic side effects, and induce a low level of cytokine release, and can also effectively eliminate various subtypes of B lymphocytes in peripheral blood.
[0011] Preferably, the deleted amino acids include: (1) 107K and 108R, (2) 106I, 107K and 108R or (3) 105V, 106L and 107G.
[0012] SEQ ID No. 10: FGQGTRLEI.
[0013] SEQ ID No. 11: FGQGTRLE.
[0014] SEQ ID No. 12: FGTGTKVT.
[0015] SEQ ID No. 13: GFTFNDYA.
[0016] SEQ ID No. 14: ISWNSGSI.
[0017] SEQ ID No. 15: AKDIQYGNYYYGMDV.
[0018] SEQ ID No. 16: QSVSSY.
[0019] SEQ ID No. 17: DAS.
[0020] SEQ ID No. 18: QQRSNWPIT.
[0021] SEQ ID No. 19: GFTFNTYA.
[0022] SEQ ID No. 20: IRSKYNNYAT.
[0023] SEQ ID No. 21: VRHGNFGTSYVSWFAY.
[0024] SEQ ID No. 22: TGAVTTSNY.
[0025] SEQ ID No. 23: GTN.
[0026] SEQ ID No. 24: ALWYSNLWV.
[0027] Preferably, the connection mode of the scFv structure is VL-(G4S)4-VH-Hinge-Fc, VL is the light chain variable region, (G4S)4 is 4 groups of sequences consisting of 4 glycine residues and 1 serine residue, VH is the heavy chain variable region, Hinge is the hinge region, and Fc is one chain of the Fc fragment.
[0028] Preferably, the heavy chain of the Fab structure is connected in a manner of VH-CH1-Hinge-Fc, VH is the heavy chain variable region, CH1 is the heavy chain constant region CH1, Hinge is the hinge region, Fc is the other chain of the Fc fragment, and the light chain is connected in a manner of VL-CL, VL is the light chain variable region, and CL is the light chain constant region.
[0029] Preferably, the amino acid sequence of the scFv structure includes the sequence shown in SEQ ID No.3, SEQ ID No.4 or SEQ ID No.5.
[0030] Preferably, the heavy chain of the Fab structure comprises the amino acid sequence shown in SEQ ID No.6, and the light chain comprises the amino acid sequence shown in SEQ ID No.7.
[0031] SEQ ID No.3:
[0032] EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIGGGGSGGGGSGGGG SGGGGSEVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQG TTVTVSSGEPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTDDDVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.
[0033] SEQ ID No.4:
[0034] EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSGEPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTDDDVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
[0035] SEQ ID No.5:
[0036] EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGTGTKVTGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYCAKDIQYGNYYYGMDVWGQG TTVTVSSGEPKSSDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTDDDVLDSDGSFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK。
[0037] SEQ ID No.6:
[0038] EVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAMYYCVRHGNFGTSYVSWFAYWGQGTLVTSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPPAEAPEAGGPSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTKKKLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.
[0039] SEQ ID No.7:
[0040] DIQMTQEPSLTTSPGGTVTLTCRSSTGAVTTSNYANWVQEKPGQAPRGLIGGTNKRAPGTPARFSGSLIGGKAALTITGVQPEDEAIYFCALWYSNLWVFGGGTKLEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
[0041] As an embodiment of the bispecific antibody of the present invention, the CH3 domain in the Fc region connected by the hinge region sequence in the first antigen binding domain and the CH3 domain in the Fc region connected by the hinge region sequence in the second antigen binding domain contain amino acid modifications with opposite charges to form a heterodimer Fc region, and such amino acid modifications with opposite charges can promote the formation of heterodimers.
[0042] More specifically, in the bispecific antibody, the CH3 domain in the Fc region connected by the hinge sequence in the first antigen-binding domain contains P395K, P396K, and V397K mutations, and the CH3 domain in the Fc region connected by the hinge sequence in the second antigen-binding domain contains T394D, P395D, and P396D mutations; or the CH3 domain in the Fc region connected by the hinge sequence in the first antigen-binding domain contains T394D, P395D, and P396D mutations, and the CH3 domain in the Fc region connected by the hinge sequence in the second antigen-binding domain contains P395K, P396K, and V397K mutations.
[0043] As a preferred embodiment of the bispecific antibody of the present invention, the heavy chain constant region of the bispecific antibody is derived from a human IgG1 or IgG4 antibody.
[0044] In the present invention, the bispecific antibody is named CD20×CD3 BsAb, and antibodies with different sequence structures are distinguished by V1~V6, such as CD20×CD3 BsAb V1, CD20×CD3 BsAb V2, ... CD20×CD3 BsAb V6.
[0045] In a second aspect, the present invention provides a nucleic acid encoding the bispecific antibody described in the first aspect.
[0046] In a third aspect, the present invention provides a recombinant vector comprising the nucleic acid described in the second aspect.
[0047] Preferably, the recombinant vector may be in the form of a plasmid vector or a viral vector.
[0048] In a fourth aspect, the present invention provides a recombinant cell, wherein the recombinant cell contains the nucleic acid described in the second aspect.
[0049] Preferably, the starting cell of the recombinant cell can be a mammalian cell. More preferably, the starting cell is a CHO cell or a 293F cell.
[0050] In a fifth aspect, the present invention provides a method for preparing the bispecific antibody according to the first aspect, the preparation method comprising:
[0051] Inserting the nucleic acid described in the second aspect into an expression vector to obtain a recombinant vector, introducing the recombinant vector into a host cell, culturing the host cell, and isolating and purifying the bispecific antibody, or,
[0052] The nucleic acid described in the second aspect is integrated into the host cell genome, the host cells are cultured, and the bispecific antibodies are isolated and purified.
[0053] As a preferred embodiment of the host cell of the present invention, the host cell is a mammalian cell. More preferably, the host cell is a CHO cell or a 293F cell.
[0054] In a sixth aspect, the present invention provides an antibody conjugate, wherein the antibody conjugate comprises the bispecific antibody described in the first aspect and a conjugated substance conjugated thereto.
[0055] The bispecific antibodies designed based on the present invention can be further used to construct antibody conjugates and develop therapeutic or diagnostic reagents.
[0056] Preferably, the coupling substance includes at least one of a cytotoxin, a radioisotope, a luminescent substance, a color-developing substance or an enzyme.
[0057] In a seventh aspect, the present invention provides a pharmaceutical composition, wherein the pharmaceutical composition comprises the bispecific antibody described in the first aspect.
[0058] In an eighth aspect, the present invention provides use of the bispecific antibody described in the first aspect in the preparation of a medicament for treating tumors or autoimmune diseases.
[0059] The CD20×CD3 bispecific antibody constructed in the present invention has strong specific cell killing activity through targeted optimization design, can significantly kill CD20 positive cells and inhibit the growth of CD20 positive tumor cells in mice, and can deeply and persistently eliminate B cells in animals. At the same time, the cytokine release level caused in and outside the animal body is low, so it has lower toxic side effects and can be used to treat recurrent / refractory tumors or B cell-related autoimmune diseases.
[0060] Preferably, the tumor comprises a B cell-related malignancy.
[0061] Preferably, the B cell-related malignant tumor includes at least one of acute B lymphocytic leukemia (B-ALL), diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), non-Hodgkin's lymphoma (NHL), chronic myeloid leukemia (CML) or Burkitt's lymphoma.
[0062] Preferably, the autoimmune disease includes an autoimmune disease caused by abnormal B cells.
[0063] Preferably, the autoimmune disease includes at least one of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or multiple sclerosis (MS).
[0064] Compared with the prior art, the present invention has at least the following beneficial effects:
[0065] (1) The present invention designs a new bispecific antibody, which effectively solves the common mismatch problems between heavy chains and between heavy and light chains in the production process of bispecific antibodies, achieves a high proportion of correct pairing, and thus improves the uniformity and stability of the product;
[0066] (2) The present invention modifies the C-terminus of the FR4 sequence of the light chain in the scFv structure of the bispecific antibody, thereby significantly increasing the expression level of the antibody molecule, which is conducive to large-scale production; in addition, it can also improve the binding affinity to CD20-positive tumor cells (such as Raji cells or Daudi cells);
[0067] (3) When the bispecific antibody of the present invention is co-incubated with peripheral blood mononuclear cells (PBMC) in vitro, the activation of T cells is weak, only very little IL-6 release is induced, and the toxic side effects are small, which is conducive to improving safety;
[0068] (4) In the repeated-dose toxicity study in rhesus monkeys, the bispecific antibody of the present invention induced a low level of cytokine release, only causing a weak increase in IL-6 after the first dose, which then returned to the pre-dose level. The other cytokines did not change significantly after administration, indicating that the risk of cytokine storm can be effectively reduced;
[0069] (5) In the repeated-dose toxicity study in rhesus monkeys, the detection results of various subtypes of B cells in the peripheral blood of the bispecific antibody of the present invention showed that at the end of the dosing period, various subtypes of B lymphocytes in the peripheral blood could be effectively cleared, indicating that it has a good therapeutic effect in the treatment of B cell-related autoimmune diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0070] Figure 1A Schematic diagram of the four-chain structure of the bispecific antibody of the present invention;
[0071] Figure 1B Schematic diagram of the three-chain structure of the bispecific antibody of the present invention;
[0072] Figure 2A Non-reduced and reduced electrophoresis gel images of CD20×CD3 BsAb V1, CD20×CD3 BsAb V2, and CD20×CD3 BsAb V3;
[0073] Figure 2B Non-reduced and reduced electrophoresis gel images of CD20×CD3 BsAb V2, CD20×CD3 BsAb V3, CD20×CD3 BsAb V4, CD20×CD3BsAb V5, and CD20×CD3 BsAb V6;
[0074] Figure 3A The graphs show the binding results of CD20×CD3 BsAb V1, CD20×CD3 BsAb V2 and CD20×CD3 BsAb V3 to human CD3 antigen;
[0075] Figure 3B It is a graph showing the binding results of CD20×CD3 BsAb V2, CD20×CD3 BsAb V3, CD20×CD3 BsAb V4, CD20×CD3BsAb V5 and CD20×CD3 BsAb V6 to human CD3 antigen;
[0076] Figure 4A This is a graph showing the binding results of CD20×CD3 BsAb V1, CD20×CD3 BsAb V2 and CD20×CD3 BsAb V3 to Raji cells;
[0077] Figure 4BThis is a graph showing the binding results of CD20×CD3 BsAb V1, CD20×CD3 BsAb V2 and CD20×CD3 BsAb V3 to Daudi cells;
[0078] Figure 4C This is a graph showing the binding results of CD20×CD3 BsAb V2, CD20×CD3 BsAb V3, CD20×CD3 BsAb V4, CD20×CD3BsAb V5 and CD20×CD3 BsAb V6 to Raji cells;
[0079] Figure 4D This is a graph showing the binding results of CD20×CD3 BsAb V2, CD20×CD3 BsAb V3, CD20×CD3 BsAb V4, CD20×CD3BsAb V5 and CD20×CD3 BsAb V6 to Daudi cells;
[0080] Figure 5A Figure 2 is the tumor killing result diagram of CD20×CD3 BsAb V1, CD20×CD3 BsAb V2 and CD20×CD3 BsAb V3;
[0081] Figure 5B The graphs show the tumor killing results of CD20×CD3 BsAb V2, CD20×CD3 BsAb V3, CD20×CD3 BsAb V4, CD20×CD3BsAb V5, and CD20×CD3 BsAb V6;
[0082] Figure 6 The in vitro cytokine (IL-2, IL-6, IFN-γ, TNF-α) release results of CD20×CD3 BsAb V6 are shown in Figure A, IFN-γ, IL-2, IL-6, IL-6, and TNF-α, respectively. Figure A shows the results of IFN-γ, Figure B shows the results of IL-2, Figure C shows the results of IL-6, and Figure D shows the results of TNF-α.
[0083] Figure 7 This is a graph showing the anti-tumor effect of CD20×CD3 BsAb V6 in mice;
[0084] Fig. 8A CD20×CD3 BsAb V6 in repeated dosing studies in rhesus monkeys + Figure 1. B lymphocyte phenotype test results.
[0085] Figure 8B CD20×CD3 BsAb V6 in a repeated-dose study in rhesus monkeys + Figure 1. B lymphocyte phenotype test results.
[0086] Figure 8C CD20×CD3 BsAb V6 in repeated dosing studies in rhesus monkeys + / CD21 + Figure 1. B lymphocyte phenotype test results.
[0087] Fig. 9 This is a graph showing the detection results of cytokine (IL-2, IL-6, IL-10, IFN-γ) release in repeated administration experiments of CD20×CD3 BsAb V6 in rhesus monkeys. DETAILED DESCRIPTION
[0088] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and through specific implementation methods. However, the following examples are only simplified examples of the present invention and do not represent or limit the scope of protection of the present invention. The scope of protection of the present invention shall be subject to the claims.
[0089] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0090] Unless otherwise defined, scientific and technical terms and abbreviations used in conjunction with the present invention shall have the meanings commonly understood by ordinary technicians in the field to which the present invention belongs. Some of the terms and abbreviations used in the present invention are listed below.
[0091] Antibody: antibody, Ab;
[0092] Immunoglobulin: immunoglobulin, Ig;
[0093] Heavy chain: heavy chain, HC;
[0094] Light chain: light chain, LC;
[0095] Heavy chain variable domain: heavy chain variable domain, VH;
[0096] Heavy chain constant domain: heavy chain constant domain, CH;
[0097] Light chain variable domain: light chain variable domain, VL;
[0098] Light chain constant domain: light chain constant domain, CL;
[0099] Antigen binding region: antigen binding fragment, Fab;
[0100] Hinge region: hinge region;
[0101] Framework region: framework region, FR
[0102] Fc region: fragment crystallizable region, Fc region;
[0103] Monoclonal antibodies: monoclonal antibodies, mAbs;
[0104] Antibody-dependent cell-mediated cytotoxicity: antibody-dependent cell-mediated cytotoxicity, ADCC;
[0105] Complement dependent cytotoxicity: complement dependent cytotoxicity, CDC;
[0106] Natural killer cell: natural killing cell, NK cell;
[0107] Bispecific antibody: bispecific antibody, BsAb;
[0108] T cell receptor: T cell receptor, TCR;
[0109] Major histocompatibility complex: major histocompatibility complex, MHC;
[0110] Complementarity determining region: complementarity determining region, CDR, refers to the antigen complementary binding region of an antibody;
[0111] Immunoreceptor tyrosine-based activation motif: ITAM;
[0112] Single-chain variable region antibody fragment (also known as single-chain antibody): single-chain variable fragment, scFv;
[0113] Adoptive immunotherapy: adoptive cellular immunotherapy, ACI;
[0114] Lymphokine-activated killer cell: lymphokine-activated killer cell, LAK cell;
[0115] Tumor Infiltrating Lymphocyte: Tumor Infiltrating Lymphocyte, TIL cell;
[0116] Cytokine-induced killer cells: cytokine-induced killer cell, CIK cells;
[0117] Non-Hodgkin Lymphoma: Non-Hodgkin Lymphoma, NHL;
[0118] Diffuse large B-cell lymphoma: DLBCL;
[0119] B-acute lymphoblastic leukemia: B-ALL;
[0120] Chronic Lymphocytic Leukemia: CLL;
[0121] Follicular Lymphoma: FL;
[0122] Chronic Myelocytic Leukemia: Chronic Myelocytic Leukemia, CML;
[0123] Burkitt lymphoma: Burkitt lymphoma, BL;
[0124] Systemic Lupus Erythematosus: Systemic Lupus Erythematosus, SLE;
[0125] Rheumatoid Arthritis: Rheumatoid Arthritis, RA;
[0126] Multiple Sclerosis: Multiple Sclerosis, MS;
[0127] The operating steps of the molecular cloning, cell culture, protein purification, animal model and other experiments described in the invention are conventional steps widely used in the field. Unless otherwise defined, the relevant terms used in the present invention have the same meanings as those commonly understood in the technical field.
[0128] The term "amino acid" refers to one of the 20 naturally occurring amino acids or any non-natural analogs that may be present in a specific defined position. The three-letter abbreviations of amino acids and single-letter abbreviations of nucleotides mentioned in the present invention are generally accepted in the technical field, and the single-letter abbreviations of amino acids are the forms recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Unless otherwise specified, the variable region amino acid numbering of the antibody of the present invention uses the coding scheme described by Kabat et al. in 1991, i.e., "Kabat index" or "Kabat numbering" (Kabat, EA et al. Sequences of Proteins of Immunological Interest, 5th ed., NIH Publication No. 91-3242, Bethesda, MD.: 1991). Unless otherwise specified, the constant region amino acid numbering of the antibody of the present invention uses the EU index (Edelman GM, et.al. Proc Natl Acad Sci USA 1969, 63: 78-85.).
[0129] The "amino acid mutation" of the present invention refers to amino acid substitution, insertion, deletion and modification in a polypeptide sequence, as well as any combination of amino acid substitution, insertion, deletion and modification. The preferred amino acid modification herein is substitution. "Amino acid substitution" or "substitution" in the present invention refers to replacing an amino acid at a specific position in a parent polypeptide sequence with another amino acid. For example, substitution C220S refers to a variant polypeptide in which the aminocysteine at position 220 of the polypeptide has been replaced by the amino acid serine. Amino acid mutation can be achieved by molecular cloning or chemical methods, and molecular cloning methods include PCR, site-directed mutagenesis, total gene synthesis, etc.
[0130] The singular terms of the present invention include the plural and the plural meaning includes the singular meaning. Unless otherwise specified, the nucleotide sequences of the present invention are arranged and written from left to right in the direction from the 5' end to the 3' end. Unless otherwise specified, the amino acid sequences of the present invention are arranged and written from left to right in the direction from the amino terminus (N terminus) to the carboxyl terminus (C terminus).
[0131] The terms "peptide chain", "polypeptide chain" and "protein" refer to molecules in which two or more amino acids are connected by peptide bonds, including natural proteins, artificial proteins, protein fragments, mutant proteins, fusion proteins, etc.
[0132] The term "domain" refers to a specific structural region in a biological macromolecule with independent function. The domain has an independent tertiary structure, and its function is not dependent on the rest of the biological macromolecule. The domain in the present invention specifically refers to such a region in a protein, such as the heavy chain variable region VH domain and the light chain variable region VL domain. The domains combine with each other to form a large domain.
[0133] The term "antibody" refers to an immunoglobulin molecule that contains at least one antigen recognition site and can specifically bind to an antigen. Here, the term "antigen" is a substance that can induce an immune response in the body and specifically bind to an antibody, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, hapten, or a combination of the above substances. The binding of an antibody to an antigen is mediated by the interaction formed between the two, including hydrogen bonds, van der Waals forces, ionic bonds, and hydrophobic bonds. The term "antibody" mentioned in the present invention includes monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, antibody fragments, multispecific antibodies (e.g., bispecific antibodies) containing at least two different epitope binding domains, human antibodies, humanized antibodies, post-translationally modified antibodies, camel antibodies, chimeric antibodies, fusion proteins containing antibody antigenic determinants, and any other modified immunoglobulin molecules containing antigen recognition sites, as long as these antibodies exhibit the desired biological activity. Specifically, antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules containing at least one antigen binding site.
[0134] The terms "Fab", "Fab region", "Fab fragment" or "Fab molecule" are antigen-binding fragments comprising the VH domain, CH1 domain of an immunoglobulin heavy chain and the VL domain, CL domain of a light chain, the first constant region domain CH1 of the heavy chain combined with the constant region domain CL of the light chain, and the variable region domain VH of the heavy chain combined with the variable region domain VL of the light chain.
[0135] The term "single-chain variable region antibody fragment" or "scFv" refers to a fusion protein of the immunoglobulin heavy chain variable region VH and the light chain variable region VL, including different combinations of N-terminal VH and N-terminal VL, which can be prepared using conventional molecular cloning methods for constructing recombinant proteins (Sambrook JF, EF et al. Molecular cloning: a laboratory manual. 4th ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York: 2012).
[0136] The term "Fc", "Fc region" or "Fc fragment" refers to the effector region of an antibody, which can cause CDC, ADCC, ADCP, cytokine release, etc. The natural antibody Fc is usually composed of two identical protein fragments, which contain two or three immunoglobulin constant region domains. The Fc described in the present invention includes natural Fc and mutated Fc. Under experimental conditions, the fragments generated by papain cleavage of immunoglobulin monomers are Fab and Fc, respectively.
[0137] The term "hinge" or "hinge region" refers to the flexible polypeptide comprising the amino acids between the first and second constant domains (CH1 and CH2) of an antibody.
[0138] The term "(G4S)4" refers to a sequence consisting of 4 groups of 4 glycine residues and 1 serine residue.
[0139] The present invention further comprises nucleic acid sequences encoding these polypeptide chains. In the process of expressing the antibody, the nucleic acid sequence is inserted into a suitable vector, including but not limited to plasmids, phage expression vectors, cosmids, artificial chromosomes, phages and animal viruses. The expression vector contains elements for regulating expression, including but not limited to promoters, transcription initiation sequences, enhancers, signal peptide sequences, etc. Promoters include but are not limited to T7 promoters, T3 promoters, SP6 promoters, β-actin promoters, EF-1α promoters, CMV promoters and SV40 promoters. The expression vector can be transferred into the host cell using suitable methods known in the art, including but not limited to calcium phosphate precipitation, liposome transfection, electroporation, and PEI (polyethyleneimine) transfection.
[0140] The term "monoclonal antibody" or "monoantibody" refers to an antibody molecule composed of a single molecule. Monoclonal antibodies have a monovalent affinity and bind to the same epitope (the part of the antigen that the antibody recognizes).
[0141] The term "antigen binding site" refers to one or more amino acid residues that directly interact with the antigen-binding molecule. The antigen binding site of an antibody is composed of the antigen complementarity determining region (CDR). Natural immunoglobulin molecules usually contain two antigen binding sites, and Fab molecules usually contain one antigen binding site.
[0142] The term "antigenic complementarity determining region (CDR)" or "hypervariable region (HVR)" refers to a region where the composition and order of amino acid residues at certain specific positions are highly variable.
[0143] The term "framework region (FR)" refers to the part of the V region other than the CDR, where the amino acid substitution frequency is low, which helps stabilize the structure of the CDR. The composition of CDR and FR in the variable region is "FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4".
[0144] The term "light chain" or "L chain" refers to a polypeptide chain consisting of approximately 214 amino acid residues with a molecular weight of approximately 24kDa. Each light chain contains two cyclic peptides formed by intrachain disulfide bonds. L chains can be divided into κ and λ types, and an antibody molecule can only have one of the two types of light chains.
[0145] The term "heavy chain" or "H chain" refers to a polypeptide chain consisting of approximately 450 to 550 amino acid residues with a molecular weight of approximately 55 or 75 kDa. According to the difference in antigenicity of the H chain, it can be divided into five categories: μ chain, γ chain, α chain, δ chain and ε chain. The molecules that form a complete Ig with different H chains and L chains (κ or λ chains) are called IgM, IgG, IgA, IgD and IgE respectively.
[0146] The term "CD20" refers to the B lymphocyte-restricted differentiation antigen encoded and expressed by the human MS4A1 gene (human CD20 UniProt Entry No. P11836), including variants and subtypes of human CD20 protein naturally expressed by cells and expressed by transfected exogenous genes, and homologous proteins of other species (such as the crab-eating CD20 protein).
[0147] The term "CD3" refers to cluster of differentiation-3 protein, which is a component of the T cell receptor complex (TCR) expressed on the surface of T cells. It is a homologous or heterologous dimer composed of four peptide chains: CD3δ (human CD3δ UniProt Entry No. P0423), CD3ε (human CD3ε UniProt EntryNo. P07766), CD3γ (human CD3γ UniProt Entry No. P09693) and CD3ζ (human CD3ζ UniProtEntry No. P20963). Unless explicitly stated, such as "cynomolgus monkey CD3" or "mouse CD3", the "CD3" mentioned in the present invention refers to human CD3.
[0148] The term “EC 50 "The concentration for 50% of maximal effect" refers to the antibody concentration that causes 50% of the maximum effect.
[0149] The present invention relates to a pharmaceutical composition comprising an antibody or antibody fragment, a bispecific antibody or an antibody conjugate of the present invention, and optionally a pharmaceutically acceptable carrier, a surfactant and / or a diluent. In some embodiments, in addition to the antibody, bispecific antibody or antibody conjugate of the present invention, the pharmaceutical composition further comprises one or more additional therapeutic agents. In some embodiments, the additional therapeutic agents include but are not limited to chemotherapeutic agents, growth inhibitors, cytotoxic agents, agents for radiotherapy, anti-angiogenic agents, apoptotic agents, anti-tubulin agents and other agents for treating cancer.
[0150] The term "host cell" refers to cells into which exogenous nucleic acid has been introduced and their progeny, which can be transformed or transfected with nucleotides encoding polypeptides to express exogenous polypeptides. The host cells described in the present invention include, but are not limited to, 293F cells (human embryonic kidney cells), CHO cells (Chinese hamster ovary cells), BHK cells (Baby Hamster Kidney), myeloma cells, yeast, insect cells or prokaryotic cells such as Escherichia coli, etc. It should be noted that the "host cell" described in the present invention refers not only to cells into which exogenous nucleic acid has been introduced, but also to the progeny of the cell. Since the progeny cells will mutate during cell division, they still fall within the scope of the term described in the present invention.
[0151] The term "NHL" stands for Non-Hodgkin Lymphoma (NHL), which is a general term for a group of malignant tumors originating from lymph nodes and lymphatic tissues, including all malignant lymphomas that are not Hodgkin lymphomas. The etiology and pathogenesis of non-Hodgkin lymphoma are not yet fully understood. It is generally believed that it is related to risk factors such as infection, immune status, environment and diet. Under the influence of these risk factors, cancer genes in B cells and T cells can be activated and tumor suppressor genes can be inactivated, causing uncontrolled lymphocyte proliferation and eventually forming non-Hodgkin lymphoma. Depending on the type of lymphocytes of origin, it can be divided into B cell lymphoma, T cell lymphoma and NK / T cell lymphoma. The World Health Organization (WHO) divides non-Hodgkin lymphoma into highly aggressive lymphoma, aggressive lymphoma and indolent lymphoma.
[0152] The term "SLE" refers to systemic lupus erythematosus (SLE), an autoimmune disease that forms and mediates organ and tissue damage with pathogenic autoantibodies and immune complexes, mainly occurring in women of childbearing age. The pathogenesis of this disease is complex, characterized by the involvement of multiple systems and immune abnormalities. The salient feature of SLE is the production of autoantibodies, the formation of immune complexes that precipitate at the vascular level, leading to multi-organ damage. The underlying mechanisms of autoantibody-induced tissue damage and systemic inflammation are still not fully understood. Disease manifestations range from mild to severe, potentially life-threatening, and exhibit acute, subacute, and chronic progression patterns.
[0153] The term "RA" stands for rheumatoid arthritis (RA), a systemic autoimmune disease with erosive arthritis as the main manifestation. The clinical manifestations are symmetrical, persistent polyarthritis mainly affecting small joints such as the hands and wrists. The pathological manifestations are chronic inflammation of the synovial membrane, pannus formation, and destruction of articular cartilage and bone, which can eventually lead to joint deformity and loss of function. The cause of the disease is still under exploration, but studies have shown that it may be closely related to factors such as autoimmunity, genetics, and microbial infection.
[0154] The term "MS" stands for Multiple Sclerosis (MS), an autoimmune disease characterized by inflammatory demyelinating lesions in the white matter of the central nervous system. The most commonly affected parts of the disease are the periventricular white matter, optic nerves, spinal cord, brainstem and cerebellum. The main clinical features are multiple lesions scattered in the white matter of the central nervous system, remission and relapse during the course of the disease, spatial multiplicity of symptoms and signs, and temporal multiplicity of the course of the disease. The etiology and pathogenesis of MS have not yet been fully clarified. Research in recent years has proposed a multifactorial etiology theory of the combined effects of autoimmunity, viral infection, genetic predisposition, environmental factors and individual susceptibility factors.
[0155] Example 1
[0156] In this example, the expression vector of CD20×CD3 BsAbs was constructed.
[0157] (1) Design of bispecific antibody structure
[0158] The antibody Fc region was partially sequenced with reference to the method of CN107106682A, wherein the CH3 domain of the Fc region connected to the CD3 antigen binding domain contained the following mutations: P395K, P396K, V397K, the mutations were marked as OA, and were positively charged; the CH3 domain of the Fc region connected to the CD20 antigen binding domain contained the following mutations: T394D, P395D, P396D, the mutations were marked as OB, and were negatively charged, and OA and OB attracted each other to form a heavy chain heterodimer.
[0159] The following methods were used to design expression vectors to study the effect of their structure on antibody activity:
[0160] Four-chain structure ( Figure 1A ): It is composed of two different antigen binding domains and an Fc fragment. Among them, both antigen binding domains are Fab structures, the connection mode of the heavy chain is VH-CH1-Hinge-Fc, and the connection mode of the light chain is VL-CL.
[0161] Three-chain structure ( Figure 1B ): It is composed of two different antigen binding domains and an Fc fragment. The first antigen binding domain is a scFv structure, and its connection mode is VL-(G4S)4-VH-Hinge-Fc. The second antigen binding domain is a Fab structure, and its heavy chain is connected in the form of VH-CH1-Hinge-Fc, and the light chain is connected in the form of VL-CL.
[0162] The specific implementation process is as follows:
[0163] The humanized sequence GXP2 was used to construct the Fab structure that binds to the CD3 antigen. The variable region sequence of the monoclonal antibody Ofatumumab was used to construct the Fab structure and scFv structure that bind to the CD20 antigen. The expression vectors of the following antibodies were constructed respectively:
[0164] i) CD20×CD3 BsAb V1: contains four polypeptide chains, forming a bispecific antibody having a first antigen binding domain with an anti-CD20 antigen Fab structure, a second antigen binding domain with an anti-CD3 antigen Fab structure, and an Fc region. Among them, the heavy chain binding to the CD3 antigen has an amino acid sequence as shown in SEQ ID No.6, the light chain binding to the CD3 antigen has an amino acid sequence as shown in SEQ ID No.7, the heavy chain binding to the CD20 antigen has an amino acid sequence as shown in SEQ ID No.8, and the light chain binding to the CD20 antigen has an amino acid sequence as shown in SEQ ID No.9;
[0165] ii) CD20×CD3 BsAb V2: a bispecific antibody containing three polypeptide chains, forming a first antigen binding domain of the scFv structure against the CD20 antigen, a second antigen binding domain of the Fab structure against the CD3 antigen, and an Fc region. The heavy chain binding to the CD3 antigen has the amino acid sequence shown in SEQ ID No.6, and the light chain binding to the CD3 antigen has the amino acid sequence shown in SEQ ID No.7; the scFv-Fc chain binding to the CD20 antigen has the amino acid sequence shown in SEQ ID No.1;
[0166] iii) CD20×CD3 BsAb V3: A bispecific antibody containing three polypeptide chains, forming a first antigen binding domain of the scFv structure against the CD20 antigen, a second antigen binding domain of the Fab structure against the CD3 antigen, and an Fc region. The heavy chain binding to the CD3 antigen has the amino acid sequence shown in SEQ ID No.6, the light chain binding to the CD3 antigen has the amino acid sequence shown in SEQ ID No.7, and the scFv-Fc chain binding to the CD20 antigen has the amino acid sequence shown in SEQ ID No.2.
[0167] The above expression vectors were transiently transfected and purified to obtain CD20×CD3 BsAb V1, CD20×CD3BsAb V2 and CD20×CD3 BsAb V3 bispecific antibody samples. Protein concentration analysis showed that the protein expression level of each sample was low. And by comparing the killing activity of CD20-positive target cells, the "three-chain structure" (CD20×CD3 BsAb V2 and V3) showed stronger tumor killing activity than the "four-chain structure" (CD20×CD3 BsAb V1).
[0168] In the field of antibody engineering, modifying the complementary determining region (CDR) of an antibody may significantly change its affinity for the antigen. At the same time, sequence modification of FR1, FR2, FR3, and FR4 in the framework region (FR) in the variable region may also affect its affinity. Therefore, the FR4 sequence of the light chain in the scFv structure that binds to the CD20 antigen was optimized and modified. More specifically, by deleting two or three amino acids from the C-terminus of the FR4 sequence of the light chain in the scFv structure, the expression amount of the antibody is increased, thereby solving the problem in large-scale production. Specific implementation method:
[0169] i) based on CD20×CD3 BsAb V2, two amino acids 107K and 108R were deleted from the C-terminus of the FR4 sequence of the light chain in the scFv structure binding to the CD20 antigen to obtain CD20×CD3 BsAb V4, wherein the scFv-Fc chain binding to the CD20 antigen has the amino acid sequence shown in SEQ ID No. 3;
[0170] ii) Based on CD20×CD3 BsAb V2, the three amino acids 106I, 107K, and 108R were deleted from the C-terminus of the FR4 sequence of the light chain in the scFv structure that binds to the CD20 antigen to obtain CD20×CD3 BsAb V5, wherein the scFv-Fc chain that binds to the CD20 antigen has the amino acid sequence shown in SEQ ID No. 4;
[0171] iii) Based on CD20×CD3 BsAb V3, three amino acids 105V, 106L, and 107G were deleted from the C-terminus of the FR4 sequence of the light chain in the scFv structure that binds to the CD20 antigen to obtain CD20×CD3 BsAb V6, wherein the scFv-Fc chain that binds to the CD20 antigen has the amino acid sequence shown in SEQ ID No.5.
[0172] (2) Molecular cloning of expression plasmid
[0173] Using conventional molecular cloning methods, the CD3 heavy chain gene was cloned into the plasmid pFUSE-hIgG1-Fc2 (InvivoGene) to obtain an expression plasmid labeled pFUSE-CD3-HC-OA, the CD3 light chain gene was cloned into the plasmid pCDNA3.1(+) (Invitrogen) to obtain an expression plasmid labeled pCDNA3.1-CD3-LC, the CD20 heavy chain gene was cloned into the plasmid pFUSE-hIgG1-Fc2 to obtain an expression plasmid labeled pFUSE-CD20-HC-OB, and the CD20 light chain gene was cloned into the plasmid pCDNA3.1(+) to obtain an expression plasmid labeled pCDNA3.1-CD20-LC. In addition, the scFv gene of CD20 was cloned into the plasmid pFUSE-hIgG1-Fc2 to obtain an expression plasmid labeled pFUSE-CD20-scFv-OB (Vx). Table 1 shows the plasmid combination for transient transfection of bispecific antibodies.
[0174] Table 1 Plasmid combinations for transient transfection of CD20×CD3 BsAbs
[0175]
[0176] SEQ ID No.1:
[0177] EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIKRGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSGEPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTDDDVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
[0178] SEQ ID No.2:
[0179] EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGTGTKVTVLGGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYCAKDIQYGNYYYGMDVWGQ GTTVTVSSGEPKSSDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTDDDVLDSDGSFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPG.
[0180] SEQ ID No.8:
[0181] EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSASTKGPSVFPCAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSSDKTHTCPPCPPAEAPEAGGPSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTDDDVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.
[0182] SEQ ID No.9:
[0183] EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK RTVAAPSVFICPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGES.
[0184] Example 2
[0185] This example performs transient transfection and expression purification on the CD20×CD3 BsAbs in Example 1.
[0186] Plasmids were extracted using a plasmid kit (EZNA® Plasmid Midi Kit, purchased from Omega Bio-Tek). 293F cells were cultured to an appropriate density, the cell suspension was centrifuged, and the cells were resuspended in fresh culture medium (OPM-291CD05 culture medium, Shanghai Aopuma Biotechnology Co., Ltd.), and co-transfected according to the plasmid combination provided in Table 1. The transfection volume was 100 mL. The transfected cell suspension was placed in a culture shaker at 37°C in the dark, and the expression supernatant was collected by centrifugation and eluted with a well-equilibrated protein A affinity chromatography column (MabSelect SuRe TM , purchased from GE Healthcare) to capture the antibody in the supernatant, wash out the non-specifically bound proteins with the equilibration buffer, then elute with the elution buffer, collect the eluate, and analyze the sample with SDS-PAGE.
[0187] The results are as follows Figure 2A and Figure 2B As shown in Table 2, the protein expression levels of CD20×CD3 BsAb V1, CD20×CD3 BsAb V2 and CD20×CD3BsAb V3 were low. After further modification, the protein expression levels of CD20×CD3 BsAb V4, CD20×CD3 BsAb V5 and CD20×CD3 BsAb V6 were increased. Among them, the protein expression level of CD20×CD3 BsAb V6 molecule was the highest. The specific expression levels are shown in Table 2.
[0188] Table 2 Statistical table of expression levels of CD20×CD3 BsAbs
[0189]
[0190] Example 3
[0191] In this example, ELISA was performed to detect the binding ability of CD20×CD3 BsAbs to CD3 antigen.
[0192] The binding of the purified bispecific antibody to CD3 antigen was detected by ELISA.
[0193] The CD3 antigen (Acro Biosystems) was diluted with NaHCO3 buffer and then coated and blocked. The CD20×CD3 BsAbs sample, positive control CD3 monoclonal antibody and negative control hIgG were diluted with 1×PBS, with a total of 8 concentration gradients. The diluted samples were added to the blocked ELISA plate. After washing, HRP-labeled goat anti-human IgG (H+L) secondary antibody was added. Finally, TMB was used for color development, and the reaction was terminated with stop solution. The absorbance value (OD value) was measured with an ELISA reader. The logarithm of the sample concentration was used as the X-axis and the absorbance OD value was used as the Y-axis to draw a dose-response curve and calculate the EC 50 , with EC 50 Represents the ability of CD20×CD3 BsAbs to bind to the target antigen CD3.
[0194] The results are as follows Figure 3A and Figure 3B As shown, all CD20×CD3 BsAbs constructed in the present invention can bind to CD3 antigen. However, compared with CD3 monoclonal antibody, the binding force of CD20×CD3 BsAbs to CD3 antigen is significantly weakened, which is beneficial to avoid excessive activation of T cells. Since the CD3 sequence of CD20×CD3 BsAbs is the same, the optimized CD20×CD3 BsAbs have similar binding force to CD3 antigen.
[0195] Example 4
[0196] In this example, flow cytometry (FACS) was used to detect the binding of CD20×CD3 BsAbs to CD20-positive cells.
[0197] In this example, two tumor cell lines, Raji cells and Daudi cells, with different CD20 expression levels were selected as target cells. The specific steps are as follows (taking Raji cells as an example).
[0198] Collect Raji cells in a centrifuge tube, centrifuge and wash, and then dilute CD20×CD3 BsAbs, positive control anti-CD20 monoclonal antibody (Rituxan) and negative control hIgG with pre-cooled washing solution. Prepare a U-shaped 96-well plate, add equal volumes of cells and diluted samples, mix well and incubate on ice. After two washes, add secondary antibodies for incubation. Wash again, and detect the binding activity of samples to Raji cells using the PE channel of the flow cytometer.
[0199] The binding activity of the dual antibody samples to Raji cells or Daudi cells was evaluated according to the shift fold.
[0200] The results are as follows Figure 4A-4D As shown in Table 3, all CD20×CD3 BsAbs can bind to CD20-positive Raji cells or Daudi cells, among which CD20×CD3 BsAb V6 has the strongest binding activity to Raji cells or Daudi cells. According to the data in Table 3, the binding activity of CD20×CD3 BsAb V1, V2 and V3 to Raji cells is similar to that of the positive control Rituxan to Raji cells; according to the data in Table 4, the binding activity of CD20×CD3 BsAb V1 to Daudi cells is similar to that of Rituxan to Daudi cells, and the binding activity of CD20×CD3 BsAb V2 and CD20×CD3 BsAb V3 to Daudi cells is weaker than that of the positive control and CD20×CD3 BsAb V1 to Daudi cells. According to the data in Table 5, compared with CD20×CD3 BsAb V2 and V3, the binding activity of CD20×CD3 BsAb V4, V5 and V6 to Raji cells is improved. Among them, CD20×CD3 BsAb V6 has the strongest binding activity to Raji cells, and is stronger than Rituxan's binding activity to Raji cells. According to the data in Table 6, compared with CD20×CD3 BsAb V2 and V3, CD20×CD3 BsAb V4, V5 and V6 have improved binding activity to Daudi cells. Among them, CD20×CD3 BsAb V6 has the strongest binding activity to Daudi cells.
[0201] Table 3 Binding of four-chain and three-chain CD20×CD3 BsAbs to Raji cells
[0202]
[0203] Table 4 Binding of four-chain and three-chain CD20×CD3 BsAbs to Daudi cells
[0204]
[0205] Table 5 Binding of triple-chain CD20×CD3 BsAbs to Raji cells
[0206]
[0207] Table 6 Binding of triple-chain CD20×CD3 BsAbs to Daudi cells
[0208]
[0209] Example 5
[0210] In this example, an in vitro cytotoxicity assay mediated by CD20×CD3 BsAbs was performed.
[0211] In this example, CD20-positive tumor cells Raji cells were used as target cells, and human blood mononuclear cells PBMC were used as effector cells.
[0212] CD20×CD3 BsAbs, isotype control bispecific antibody EX101 (HER2×CD3BsAb) and negative control hIgG were diluted in PBS buffer. Raji cells, PBMCs and gradient dilution samples were added to the cell culture plate in sequence. After mixing, the 96-well plate was placed in a 37°C, 5% CO2 incubator and detected using a lactate dehydrogenase cytotoxicity kit. The absorbance value (OD value) was measured using an ELISA reader, and the relative killing value was calculated. With the logarithm of the antibody working concentration as the X-axis and the relative killing value as the Y-axis, a dose-effect curve was drawn to calculate the half effective concentration (EC 50 ), with EC 50 The values represent the killing activity of CD20×CD3 BsAbs against Raji cells.
[0213] The results are as follows Figure 5A and Figure 5B As shown in the figure, compared with hIgG, CD20×CD3 BsAb V1, V2 and V3 can induce PBMC to kill CD20 positive tumor Raji cells, EC 50 The cytotoxicity of CD20×CD3 BsAb V2 and V3 against tumor cells was stronger than that of CD20×CD3 BsAb V1 ( Figure 5A Compared with the isotype control bispecific antibody EX101 (HER2×CD3) and hIgG, CD20×CD3 BsAb V2, V3, V4, V5, and V6 can induce PBMC to kill CD20-positive tumor Raji cells ( Figure 5B ), E.C. 50The EC values of CD20×CD3 BsAb V6 and CD20×CD3 BsAb V6 were 0.04086 nM, 0.08457 nM, 0.1299 nM, 0.1250 nM and 0.007808 nM, respectively. 50 Compared with EC of V2, V3, V4 and V5 50 5~17 times lower.
[0214] In summary, optimizing the FR4 sequence of the light chain in the scFv structure of the CD20 antigen can significantly improve the expression level, cell binding ability, and tumor cell killing ability. Among them, CD20×CD3 BsAb V6 has a high expression level, which is similar to CD20 + The binding affinity to cells (Raji, Daudi) and the cytotoxic activity against CD20-positive tumor cells were strong, therefore, CD20×CD3 BsAb V6 was selected for subsequent safety and efficacy studies.
[0215] Example 6
[0216] In this example, an in vitro cytokine release assay of CD20×CD3 BsAb V6 was performed.
[0217] In this example, CD20×CD3 BsAb V6 was co-incubated with human PBMC cells to evaluate the ability of CD20×CD3 BsAbV6 to cause cytokine release. CD20×CD3 BsAb V6, positive control anti-CD3 monoclonal antibody and negative control (IgG) were gradient diluted with RPMI 1640 medium, with a total of 8 concentration gradients. Prepare a 96-well cell culture plate, add equal volumes of PBMC and diluted samples, mix well, and place the 96-well plate in a 37°C incubator for static culture overnight. Take out the 96-well cell culture plate and take the supernatant to detect the content of cytokines such as IFN-γ, IL-2, TNF-α and IL-6.
[0218] 1) IFN-γ: Detection was performed according to the instructions provided by the human interferon γ detection kit (Abcam, Cat. ab48490);
[0219] 2) IL-2: Detection was performed according to the instructions provided by the human interleukin-2 detection kit (R&D Systems, Cat. DY202);
[0220] 3) TNF-α: detected according to the instructions provided by the human tumor necrosis factor α detection kit (Beyotime, Cat. PT518);
[0221] 4) IL-6: Detection was performed according to the instructions provided by the human interleukin-6 detection kit (Beyotime, Cat. PI330).
[0222] The results are as follows Figure 6 As shown in the figure, CD3 monoclonal antibody (positive antibody) can stimulate PBMC to release a variety of cytokines, including IFN-γ, IL-2, TNF-α, IL-6, etc. Since human PBMC contains CD20-positive target cells (B cells) and CD3-positive effector cells (T cells). When co-incubated with PBMC, CD20×CD3 BsAb V6 can bind to B cells and T cells at the same time, forming an immune bridge between them, thereby activating T cells to produce cytokines. The results show that the ability of CD20×CD3 BsAb V6 to stimulate T cells to produce cytokines is significantly weaker than that of CD3 monoclonal antibody, and only induces very little IL-6 release, which can reduce the risk of cytokine storm and has lower toxic side effects.
[0223] Example 7
[0224] In this example, the anti-tumor activity of CD20×CD3 BsAb V6 in mice was detected.
[0225] In this example, CD3 humanized BALB / c mice (BALB / c-hCD3E) were selected for in vivo efficacy evaluation. A stable cell line of mouse B cell lymphoma A20 expressing human CD20 protein (A20-hCD20) was constructed, and a tumor model was established in CD3 humanized mice (BALB / c-hCD3E) to evaluate the in vivo anti-tumor effect of CD20×CD3 BsAb V6.
[0226] A20-hCD20 cells were inoculated into the right forelimb of mice. When the average tumor volume reached 50-100 mm 3 At the time of the experiment, 36 mice were randomly divided into 6 groups, namely, negative control saline group, CD20×CD3 BsAb V6 dose group (0.02, 0.1, 0.5, 2 and 5 mg / kg). The drug was injected into the tail vein (iv) for 5 times, and the tumor size was observed regularly and the mice were weighed. The tumor volume was calculated as follows: tumor volume (mm 3 ) = 0.5 × (tumor long diameter × tumor short diameter 2 The tumor volume was used to calculate the tumor proliferation rate (T / C%) and tumor inhibition rate (TGI%). The efficacy was evaluated based on the tumor inhibition rate (TGI%).
[0227] The results are as follows Figure 7As shown, the CD20×CD3 BsAb V6 treatment group (0.1 mg / kg ~5 mg / kg) has a significant tumor inhibition effect in mice. Table 7 shows the tumor inhibition of each CD20×CD3 BsAb V6 treatment group on day 11. Compared with the G1 group (normal saline), the tumor inhibition rates of the G2 group 5 mg / kg, the G3 group 2 mg / kg, and the G4 group 0.5 mg / kg on day 11 were 100%; the tumor inhibition rates of the G5 group 0.1 mg / kg on day 11 were 96.11%; and the tumor inhibition rates of the G6 group 0.02 mg / kg on day 11 were 49.57%.
[0228] In summary, CD20×CD3 BsAb V6 can significantly inhibit tumor growth in mice at a low dose of 0.1 mg / kg.
[0229] Table 7 Tumor inhibition in each treatment group of CD20×CD3 BsAb V6 at D11
[0230]
[0231] Example 8
[0232] In this example, CD20×CD3 BsAb V6 was used to conduct a repeated administration toxicity study in rhesus monkeys.
[0233] A total of 40 rhesus monkeys (provided by: Hubei Tianqin Biotechnology Co., Ltd. Suizhou Branch; production license number: SCXK (E) 2016-0010; animal quality certificate number: No. 421218300000117) were used in the experiment and divided into 4 groups (5 monkeys / sex / group): excipient control group, CD20×CD3 BsAb V6 low-dose group (0.2 mg / kg), CD20×CD3 BsAb V6 medium-dose group (0.6 mg / kg), CD20×CD3 BsAb V6 high-dose group (1.2 mg / kg). The drug was administered by intravenous injection for a total of 5 times. The day when the animals enter this experiment is defined as the first day (P1) of the Pretest Phase. By analogy, the second day is P2, the tenth day is P10, and so on. The first day of administration is defined as the first day (D1) of the Dosing Phase, and the day after the end of the Dosing Phase (D35) is defined as the first day (R1) of the Recovery Phase. Blood was collected during the pre-administration adaptation period (P10 / P11), the end of the Dosing Phase (D35), the recovery phase (R14 / R15 and R30 / R31), and the end of the recovery phase (R42) to analyze the B lymphocyte phenotype (CD20 + B cell ratio, CD20 + / CD21+ B cell proportion and CD40 + B cell ratio). Cytokines (IL-2, IL-6, IL-10, TNF-α) were detected before the first administration and 1 h, 4 h, 10 h and 24 h after administration, at the end of the administration period (D35) and at the end of the recovery period (R42).
[0234] B lymphocyte test results Figure 8A-8C As shown, at the end of the dosing period (D35), the peripheral blood CD20 in each CD20×CD3 BsAb V6 dose group was significantly higher than that before dosing and the control group. + B lymphocyte ratio, CD20 + / CD21 + B lymphocyte ratio, CD40 + The proportion of B lymphocytes decreased significantly, and CD20 + B cells, CD20 + / CD21 + B lymphocytes were completely eliminated, indicating that CD20×CD3 BsAb V6 molecules can be used to treat autoimmune diseases. In the recovery period (R14 / R15 to R30 / 31), B lymphocytes in the low-dose group showed a significant recovery trend, the medium-dose group began to gradually recover, and the high-dose group had no recovery trend. At the end of the recovery period (R42), the above indicators of the low-dose and medium-dose groups were basically restored to the pre-drug level, and the high-dose group also had a significant recovery trend, but the proportion of related B lymphocytes had not yet returned to the pre-drug level, indicating that the recovery of the proportion of B lymphocytes in the animals had a significant dose-effect relationship with the CD20×CD3 BsAb V6 dosage.
[0235] Cytokine test results Fig. 9 As shown, each dose group of CD20×CD3 BsAb V6 only caused a weak increase in IL-6 after the first administration, and then returned to the level before administration, and there was no significant change in other cytokines. The specific test results are as follows:
[0236] IL-2: 1 h after administration of CD20×CD3 BsAb V6 in each dose group, IL-2 increased slightly and returned to the pre-drug level 4 h later;
[0237] IL-6: IL-6 increased after administration of CD20×CD3 BsAb V6 in each dose group, reaching a peak at 4-10 h and returning to pre-dose levels 24 h after administration;
[0238] IL-10: There was basically no change in IL-10 release after administration of each dose group of CD20×CD3 BsAb V6;
[0239] IFN-γ: There was no significant change in IFN-γ release after administration of CD20×CD3 BsAb V6 in each dose group.
[0240] In summary, the present invention develops a bispecific antibody targeting CD20 and CD3 with strong lethality and low toxic side effects. The antibody has a "three-chain structure" and is composed of two different antigen-binding domains and an Fc fragment connected together. The antibody is further optimized and modified based on the "three-chain structure" by deleting two or three amino acids at the C-terminus of the FR4 sequence of the light chain in the scFv structure that binds to the CD20 antigen, thereby further improving the expression level of the antibody and the tumor killing ability, while reducing toxic side effects. It can also quickly and deeply eliminate different types of B cells in the peripheral blood of animals, and can be effectively used in anti-tumor and treatment of B cell-related autoimmune diseases.
[0241] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.
Claims
1. A bispecific antibody against CD20 and CD3, characterized in that: The bispecific antibody comprises a first antigen binding domain, a second antigen binding domain and an Fc fragment, wherein the first antigen binding domain specifically binds to CD20, and the second antigen binding domain specifically binds to CD3, the first antigen binding domain is an scFv structure, and two or three amino acids are deleted from the C-terminus of the framework region FR4 of the light chain variable region in the scFv structure, and the amino acid sequence of the framework region FR4 of the light chain variable region is shown in SEQ ID No. 10, SEQ ID No. 11 or SEQ ID No. 12; The second antigen binding domain is a Fab structure; The sequences of the heavy chain CDR1, CDR2 and CDR3 of the scFv structure are shown in SEQ ID No.13, SEQ ID No.14 and SEQ ID No.15, respectively, and the sequences of the light chain CDR1, CDR2 and CDR3 are shown in SEQ ID No.16, SEQ ID No.17 and SEQ ID No.18, respectively; The sequences of the heavy chain CDR1, CDR2 and CDR3 of the Fab structure are shown as SEQ ID No.19, SEQ ID No.20 and SEQ ID No.21, respectively, and the sequences of the light chain CDR1, CDR2 and CDR3 are shown as SEQ ID No.22, SEQ ID No.23 and SEQ ID No.24, respectively.
2. The bispecific antibody according to claim 1, characterized in that The connection mode of the scFv structure is VL-(G4S)4-VH-Hinge-Fc, VL is the light chain variable region, (G4S)4 is a sequence consisting of 4 groups of 4 glycine residues and 1 serine residue, VH is the heavy chain variable region, Hinge is the hinge region, and Fc is one chain of the Fc fragment; The connection mode of the heavy chain of the Fab structure is VH-CH1-Hinge-Fc, VH is the heavy chain variable region, CH1 is the heavy chain constant region CH1, Hinge is the hinge region, Fc is the other chain of the Fc fragment, and the connection mode of the light chain is VL-CL, VL is the light chain variable region, and CL is the light chain constant region.
3. The bispecific antibody according to claim 1, characterized in that The amino acid sequence of the scFv structure is shown in SEQ ID No.3, SEQ ID No.4 or SEQ ID No.5; The heavy chain amino acid sequence of the Fab structure is shown in SEQ ID No.6, and the light chain amino acid sequence is shown in SEQ ID No.
7.
4. A nucleic acid, characterized in that The nucleic acid encodes the bispecific antibody according to any one of claims 1 to 3.
5. The method for preparing a bispecific antibody according to any one of claims 1 to 3, characterized in that: The preparation method comprises: Insert the nucleic acid according to claim 4 into an expression vector to obtain a recombinant vector, introduce the recombinant vector into a host cell, culture the host cell, separate and purify to obtain a bispecific antibody.
6. An antibody conjugate, characterized in that: The antibody conjugate comprises the bispecific antibody according to any one of claims 1 to 3 and a conjugated substance conjugated thereto; The coupling substance is at least one of cytotoxin, radioisotope, luminescent substance, color-developing substance or enzyme.
7. A pharmaceutical composition, characterized in that The drug combination comprises the bispecific antibody according to any one of claims 1 to 3.
8. Use of the bispecific antibody according to any one of claims 1 to 3 in the preparation of a medicament for treating tumors or autoimmune diseases; The tumor is B-cell lymphoma and / or Burkitt lymphoma; The autoimmune disease is an autoimmune disease caused by abnormal B cells; The autoimmune disease is at least one of systemic lupus erythematosus, rheumatoid arthritis or multiple sclerosis.
